Vertex Pharmaceuticals (VRTX) Net Income - Minority (2016 - 2018)
Vertex Pharmaceuticals has reported Net Income - Minority over the past 8 years, most recently at -$28.4 million for Q3 2018.
- Quarterly results put Net Income - Minority at -$28.4 million for Q3 2018, down 133.13% from a year ago — trailing twelve months through Sep 2018 was -$28.4 million (down 133.13% YoY), and the annual figure for FY2017 was -$13.7 million, up 92.44%.
- Net Income - Minority for Q3 2018 was -$28.4 million at Vertex Pharmaceuticals, up from -$28.7 million in the prior quarter.
- Over the last five years, Net Income - Minority for VRTX hit a ceiling of -$12.2 million in Q3 2017 and a floor of -$196.0 million in Q2 2017.
- Median Net Income - Minority over the past 5 years was -$153.5 million (2015), compared with a mean of -$106.9 million.
- Biggest five-year swings in Net Income - Minority: plummeted 654.87% in 2016 and later soared 93.49% in 2017.
- Vertex Pharmaceuticals' Net Income - Minority stood at -$21.2 million in 2014, then crashed by 625.6% to -$153.7 million in 2015, then dropped by 18.19% to -$181.6 million in 2016, then skyrocketed by 92.44% to -$13.7 million in 2017, then crashed by 106.64% to -$28.4 million in 2018.
- The last three reported values for Net Income - Minority were -$28.4 million (Q3 2018), -$28.7 million (Q2 2018), and -$29.8 million (Q1 2018) per Business Quant data.